Ultragenyx Pharmaceutical Inc at Goldman Sachs Healthcare Conference Transcript
Great. Good afternoon, everyone. I'm Salveen Richter, biotechnology analyst at Goldman Sachs. And we're really pleased to have Emil Kakkis, Founder, President and CEO of Ultragenyx.
Questions & Answers
So Emil, it's been quite a few years since you founded this company; and you've emerged as a commercial story with a pipeline that continues to evolve. Just to level set, as you sit here today and you look at the commercial aspect and the pipeline and the modalities you brought in, where do you see kind of the future of Ultragenyx going?
Well, first of all, I'm very happy, at 12 years, to be a commercial company with 4 approved products; to have 5 late-stage programs, which is hard to do; and then to be heading into $420 million, $450 million revenue this year. [So an]
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
